Exelixis Inc Restructuring and Related Cost, Cost Incurred to Date
Exelixis Inc (EXEL) had Restructuring and Related Cost, Cost Incurred to Date of $20.51 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2026-02-10
- 2026-01-02: Restructuring and Related Cost, Cost Incurred to Date $20.51M.
- 2025-10-03: Restructuring and Related Cost, Cost Incurred to Date $19.82M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2026-01-02 | $20.51M 10-K · filed 2026-02-10 |
| 2025-10-03 | $19.82M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |